Literature DB >> 28151735

Do Thiopurines Reduce the Risk of Surgery in Elderly Onset Inflammatory Bowel Disease? A 20-Year National Population-Based Cohort Study.

Christopher Alexakis1, Sonia Saxena, Vivek Chhaya, Elizabeth Cecil, Vasa Curcin, Richard Pollok.   

Abstract

BACKGROUND: Evidence that thiopurines impact on the risk of surgery in elderly onset inflammatory bowel disease (EO-IBD) is lacking. We aimed to compare the rates of surgery in EO-IBD (>60 years at diagnosis) with adult-onset IBD (18-59 yrs), and examine the impact of thiopurines on surgical risk in EO-IBD.
METHODS: Using a U.K. database between 1990 and 2010, we compared rates of surgery between adult-onset IBD and EO-IBD using survival analysis. Ulcerative colitis (UC) and Crohn's disease (CD) were analyzed separately. Cox proportional hazard modeling was used to determine the adjusted relative risk of surgery. We further assessed the impact of duration of thiopurine treatment on risk of surgery.
RESULTS: We identified 2758 of 9515 patients with UC and 1349 of 6490 patients with CD, with EO-IBD. Cumulative 1, 5, and 10 years risk of colectomy was similar in EO-UC (2.2, 4.5, and 5.8%, respectively) and AO-UC (2.2, 5.0, and 7.3%, respectively; P = 0.15). Cumulative 1, 5, and 10 years risk of first intestinal surgery was lower in EO-CD (9.5, 14.6, and 17.9%, respectively) than AO-CD (12.2, 19.0, and 24.4%, respectively; P < 0.001). Early steroid use, steroid dependency, and thiopurine use was associated with higher risk of colectomy in EO-UC. Among EO-UC receiving thiopurines for >12 months, there was a 70% reduction in risk of colectomy (hazard ratio. 0.30; 95% confidence interval, 0.15-0.58). Thiopurines were not associated with a reduced risk of surgery in EO-CD.
CONCLUSIONS: Risk of colectomy in EO-UC does not differ from AO-UC, but the risk of surgery in EO-CD is significantly lower than in AO-CD. Sustained thiopurine use of 12 months or more duration in EO-UC reduces the risk colectomy, but does not impact on the risk of surgery in EO-CD. These findings are important given the greater risk of thiopurine-associated lymphoma in the elderly.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28151735     DOI: 10.1097/MIB.0000000000001031

Source DB:  PubMed          Journal:  Inflamm Bowel Dis        ISSN: 1078-0998            Impact factor:   5.325


  14 in total

Review 1.  Management of Ulcerative Colitis in the Elderly.

Authors:  Manish P Shrestha; Sasha Taleban
Journal:  Drugs Aging       Date:  2019-01       Impact factor: 3.923

Review 2.  Inflammatory Bowel Disease in the Baby to Baby Boomer: Pediatric and Elderly Onset of IBD.

Authors:  Anita Afzali; Seymour Katz
Journal:  Curr Treat Options Gastroenterol       Date:  2018-09

3.  Progression of Elderly Onset Inflammatory Bowel Diseases: A Systematic Review and Meta-Analysis of Population-Based Cohort Studies.

Authors:  Jacob J Rozich; Parambir S Dulai; Mathurin Fumery; William J Sandborn; Siddharth Singh
Journal:  Clin Gastroenterol Hepatol       Date:  2020-03-03       Impact factor: 11.382

Review 4.  Management of Inflammatory Bowel Diseases in Special Populations: Obese, Old, or Obstetric.

Authors:  Siddharth Singh; Sherman Picardo; Cynthia H Seow
Journal:  Clin Gastroenterol Hepatol       Date:  2019-11-08       Impact factor: 11.382

5.  Chemopreventive Effects of Silibinin on Colitis-Associated Tumorigenesis by Inhibiting IL-6/STAT3 Signaling Pathway.

Authors:  Rongjuan Zheng; Jiaheng Ma; Dan Wang; Wenxiao Dong; Sinan Wang; Tianyu Liu; Runxiang Xie; Li Liu; Bangmao Wang; Hailong Cao
Journal:  Mediators Inflamm       Date:  2018-10-25       Impact factor: 4.711

Review 6.  Elderly patients with inflammatory bowel disease: Updated review of the therapeutic landscape.

Authors:  Jean-Frédéric LeBlanc; Daniel Wiseman; Peter L Lakatos; Talat Bessissow
Journal:  World J Gastroenterol       Date:  2019-08-14       Impact factor: 5.742

Review 7.  Management of elderly ulcerative colitis in Japan.

Authors:  Masaaki Higashiyama; Akira Sugita; Kazutaka Koganei; Kenji Wanatabe; Yoko Yokoyama; Motoi Uchino; Masakazu Nagahori; Makoto Naganuma; Shigeki Bamba; Shingo Kato; Ken Takeuchi; Teppei Omori; Tomohisa Takagi; Satohiro Matsumoto; Mitsuo Nagasaka; Shintaro Sagami; Kazuya Kitamura; Takehiko Katsurada; Ken Sugimoto; Noritaka Takatsu; Masayuki Saruta; Toshiyuki Sakurai; Kazuhiro Watanabe; Shiro Nakamura; Yasuo Suzuki; Ryota Hokari
Journal:  J Gastroenterol       Date:  2019-04-20       Impact factor: 7.527

Review 8.  The elderly IBD patient in the modern era: changing paradigms in risk stratification and therapeutic management.

Authors:  Simon J Hong; Seymour Katz
Journal:  Therap Adv Gastroenterol       Date:  2021-07-03       Impact factor: 4.409

9.  Changing nationwide trends in endoscopic, medical and surgical admissions for inflammatory bowel disease: 2003-2013.

Authors:  Ahmir Ahmad; Anthony A Laverty; Chris Alexakis; Tom Cowling; Sonia Saxena; Azeem Majeed; Richard C G Pollok
Journal:  BMJ Open Gastroenterol       Date:  2018-03-20

10.  Trends of Medication Usage and Associated Outcomes for Taiwanese Patients with Inflammatory Bowel Disease from 2001 to 2015.

Authors:  Meng-Tzu Weng; Chien-Chih Tung; Yuan-Ting Chang; Yew-Loong Leong; Yu-Ting Wang; Jau-Min Wong; Shu-Chen Wei
Journal:  J Clin Med       Date:  2018-10-27       Impact factor: 4.241

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.